The renin‐angiotensin system (RAS) plays a pivotal role in the pathophysiology of diabetic nephropathy, and clinical trials such as IDNT and RENAAL have established the benefits of ARBs in slowing renal disease progression independent of blood pressure control [15, 44]. Here, REN is linked to kidney disorder.